Clinical Cancer Research, Vol 4, Issue 7 1803-1811, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Fas ligand is constitutively secreted by prostate cancer cells in vitro

QY Liu, MA Rubin, C Omene, S Lederman and CA Stein
Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA.

LNCaP, DU145, and PC3 prostate carcinoma cells secrete the 27-kDa soluble Fas ligand (sFasL) into their local environment. sFasL arises from the 40-kDa membrane-bound form (mFasL), which can be found on the cell surface in the LNCaP line, as demonstrated by monoclonal antibody staining. mFasL was also found in extracts of all three cell lines, as demonstrated by Western blotting. FasL mRNA was detected not only in the cell lines, but in the normal prostate as well. sFasL protein could also be detected immunohistochemically in prostate secretions and in human semen. Cleavage of mFasL to sFasL could be inhibited by several matrix metalloprotease inhibitors without a change in the cellular levels of FasL. Prostate-derived sFasL is biologically active, as demonstrated by its induction of apoptosis in Fas-positive Ramos cells, which was detected by terminal deoxynucleotidyl transferase-mediated nick end labeling assay. Mitoxantrone induces cellular apoptosis in all three prostate cancer cell lines. Mitoxantrone treatment and doxorubicin treatment also cause up-regulation of Fas, the cell surface receptor for FasL, in LNCaP cells, but not in DU145 or PC3 cells. Furthermore, the up-regulation of Fas expression by mitoxantrone at a high concentration was potentiated by hydrocortisone. When FasL interacts with its Fas, the Fas-bearing cell undergoes apoptosis. When LNCaP cells were treated with mitoxantrone and incubated with an anti-FasL monoclonal antibody, apoptosis was partially blocked. This not only further suggests that the sFasL is biologically active, but that the up-regulation of Fas in the presence of sFasL accounts, in part, for the cytotoxicity of mitoxantrone.

This article has been cited by other articles:

				J. Bertram, J. W. Peacock, C. Tan, A. L-F. Mui, S. W. Chung, M. E. Gleave, S. Dedhar, M. E. Cox, and C. J. Ong Inhibition of the Phosphatidylinositol 3'-Kinase Pathway Promotes Autocrine Fas-Induced Death of Phosphatase and Tensin Homologue-Deficient Prostate Cancer Cells. Cancer Res., May 1, 2006; 66(9): 4781 - 4788. [Abstract] [Full Text] [PDF]

				A. Hatzoglou, M. Kampa, C. Kogia, I. Charalampopoulos, P. A. Theodoropoulos, P. Anezinis, C. Dambaki, E. A. Papakonstanti, E. N. Stathopoulos, C. Stournaras, et al. Membrane Androgen Receptor Activation Induces Apoptotic Regression of Human Prostate Cancer Cells in Vitro and in Vivo J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 893 - 903. [Abstract] [Full Text] [PDF]

				D. D. Taylor, C. Gercel-Taylor, K. S. Lyons, J. Stanson, and T. L. Whiteside T-Cell Apoptosis and Suppression of T-Cell Receptor/CD3-{zeta} by Fas Ligand-Containing Membrane Vesicles Shed from Ovarian Tumors Clin. Cancer Res., November 1, 2003; 9(14): 5113 - 5119. [Abstract] [Full Text] [PDF]

				M. E. Wright, M.-J. Tsai, and R. Aebersold Androgen Receptor Represses the Neuroendocrine Transdifferentiation Process in Prostate Cancer Cells Mol. Endocrinol., September 1, 2003; 17(9): 1726 - 1737. [Abstract] [Full Text] [PDF]

				A. Omezzine, C. Mauduit, E. Tabone, N. Nabli, A. Bouslama, and M. Benahmed Caspase-3 and -6 Expression and Activation Are Targeted by Hormone Action in the Rat Ventral Prostate During the Apoptotic Cell Death Process Biol Reprod, September 1, 2003; 69(3): 752 - 760. [Abstract] [Full Text] [PDF]

				J. P. Carson, M. Behnam, J. N. Sutton, C. Du, X. Wang, D. F. Hunt, M. J. Weber, and G. Kulik Smac Is Required for Cytochrome c-induced Apoptosis in Prostate Cancer LNCaP Cells Cancer Res., January 1, 2002; 62(1): 18 - 23. [Abstract] [Full Text] [PDF]

				D. Chatterjee, I. Schmitz, A. Krueger, K. Yeung, S. Kirchhoff, P. H. Krammer, M. E. Peter, J. H. Wyche, and P. Pantazis Induction of Apoptosis in 9-Nitrocamptothecin-treated DU145 Human Prostate Carcinoma Cells Correlates with de Novo Synthesis of CD95 and CD95 Ligand and Down-Regulation of c-FLIPshort Cancer Res., October 1, 2001; 61(19): 7148 - 7154. [Abstract] [Full Text] [PDF]

				G. Bellone, C. Smirne, A. Carbone, K. Mareschi, L. Dughera, E. C. Farina, O. Alabiso, G. Valente, G. Emanuelli, and U. Rodeck Production and Pro-Apoptotic Activity of Soluble CD95 Ligand in Pancreatic Carcinoma Clin. Cancer Res., June 1, 2000; 6(6): 2448 - 2455. [Abstract] [Full Text]

				M. J. Pinkoski, T. Brunner, D. R. Green, and T. Lin Fas and Fas ligand in gut and liver Am J Physiol Gastrointest Liver Physiol, March 1, 2000; 278(3): G354 - G366. [Abstract] [Full Text] [PDF]

				A.G.S. Buggins, N. Lea, J. Gaken, D. Darling, F. Farzaneh, G.J. Mufti, and W.J.R. Hirst Effect of Costimulation and the Microenvironment on Antigen Presentation by Leukemic Cells Blood, November 15, 1999; 94(10): 3479 - 3490. [Abstract] [Full Text] [PDF]

				M. Garzotto, A. Haimovitz-Friedman, W.-C. Liao, M. White-Jones, R. Huryk, W. D. W. Heston, C. Cardon-Cardo, R. Kolesnick, and Z. Fuks Reversal of Radiation Resistance in LNCaP Cells by Targeting Apoptosis through Ceramide Synthase Cancer Res., October 1, 1999; 59(20): 5194 - 5201. [Abstract] [Full Text] [PDF]

				R. K. Srivastava, C. Y. Sasaki, J. M. Hardwick, and D. L. Longo Bcl-2–mediated Drug Resistance: Inhibition of Apoptosis by Blocking Nuclear Factor of Activated T Lymphocytes (NFAT)-induced Fas Ligand Transcription J. Exp. Med., July 19, 1999; 190(2): 253 - 266. [Abstract] [Full Text] [PDF]